| Field | Specification |
|---|---|
| Target | |
| Alternative names | Insulin-like growth factor 2 mRNA-binding protein 3; IGF2 mRNA-binding protein 3; IMP-3; IGF-II mRNA-binding protein 3; KH domain-containing protein overexpressed in cancer; hKOC; VICKZ family member 3; IGF2BP3; IMP3; KOC1; VICKZ3 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human IMP3 RNA-binding protein that act as a regulator of mRNA translation and stability. Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs. Binds to sequences in the 3'-UTR of CD44 mRNA. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone AEDB-9 is a rabbit monoclonal antibody that recognizes insulin-like growth factor 2 mRNA-binding protein 3 (gene IGF2BP3) in human, mouse and rat samples and is validated for Western blot, ICC/IF, immunoprecipitation and flow cytometry. The predicted molecular weight is 63.7 kDa, and the supplier reports an observed band at about 72 kDa.
IGF2BP3 (also called IMP3) is an oncofetal RNA-binding protein that controls the stability and translation of target mRNAs, including CD44 and IGF2. It recognizes N6-methyladenosine (m6A)-modified transcripts and is expressed mainly during development and in many cancers, where it is often used as a tumor marker in research.
| Target | Insulin-like growth factor 2 mRNA-binding protein 3 (gene IGF2BP3; UniProt O00425, human) |
|---|---|
| Clone | AEDB-9 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 63.7 kDa |
| Observed MW | 72 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Immunoprecipitation | 1:50 |
| Flow cytometry | 1:50 |
Samples with a confirmed band (WB): human HeLa cells, human 293T cells, human PC-3 cells, human HepG2 cells, human RT4 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:500 overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Immunogen
Synthetic peptide based on the sequence of human IMP3 RNA-binding protein that act as a regulator of mRNA translation and stability.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places insulin-like growth factor 2 mRNA-binding protein 3 in the nucleus and cytoplasm. Tissue expression noted by UniProt (human): Expressed in fetal liver, fetal lung, fetal kidney, fetal thymus, fetal placenta, fetal follicles of ovary and gonocytes of testis, growing oocytes, spermatogonia and semen (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Mengzhi Xu et al. (2024) Enterolactone combined with m6A Reader IGF2BP3 inhibits malignant angiogenesis and disease progression in ovarian cancer. Phytomedicine. 10.1016/j.phymed.2024.156343
